Kamada (KMDA) Cash from Investing Activities (2013 - 2026)
Kamada (KMDA) posted quarterly Cash from Investing Activities of -$41.2 million for Q1 2026, down 2721.78% year-on-year from $1.6 million in Q1 2025, and down 1384.61% on a QoQ basis from -$2.8 million in Q4 2025.
Kamada (KMDA) Cash from Investing Activities (2013 - 2026) Analysis & Trends
Kamada (KMDA) has reported Cash from Investing Activities for 14 consecutive years, with -$41.2 million the latest figure, recorded in Q1 2026.
- Quarterly Cash from Investing Activities fell 2721.78% year-over-year to -$41.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$49.6 million (down 420.92% YoY) and the FY2025 annual result came in at -$9.8 million, up 8.39% from the prior year.
- Cash from Investing Activities declined to -$41.2 million in Q1 2026 per KMDA's latest filing, from -$2.8 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for KMDA reached as high as -$1093.0 in Q1 2023 and fell as low as -$41.2 million in Q1 2026.
- A 5-year average of -$4.0 million and a median of -$2.0 million in 2023 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities surged 99.79% — and 2024, when it sank 245279.69%.
- Year by year, Cash from Investing Activities stood at -$977000.0 in 2022, then sank by 101.94% to -$2.0 million in 2023, then tumbled by 48.2% to -$2.9 million in 2024, then gained by 5.1% to -$2.8 million in 2025, then plunged by 1384.61% to -$41.2 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$41.2 million, -$2.8 million, and -$3.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Kamada | 399.49 Mn | 326.34 Mn | 19.12 Mn | -41.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.20 Mn |
| Mar 31, 2026 | -41.20 Mn |
| Dec 31, 2025 | -2.78 Mn |
| Dec 31, 2025 | -2.78 Mn |
| Sep 30, 2025 | -3.59 Mn |
| Sep 30, 2025 | -3.59 Mn |
| Jun 30, 2025 | -2.01 Mn |
| Jun 30, 2025 | -2.01 Mn |
| Mar 31, 2025 | -1.46 Mn |
| Mar 31, 2025 | -1.46 Mn |
| Dec 31, 2024 | -2.92 Mn |
| Dec 31, 2024 | -2.92 Mn |
| Sep 30, 2024 | -2.12 Mn |
| Sep 30, 2024 | -2.12 Mn |
| Jun 30, 2024 | -3.01 Mn |
| Jun 30, 2024 | -3.01 Mn |
| Mar 31, 2024 | -2.68 Mn |
| Mar 31, 2024 | -2.68 Mn |
| Dec 31, 2023 | -1.97 Mn |
| Dec 31, 2023 | -1.97 Mn |